MedTrace Logo

A Phase I Study of XH-S002 in Healthy Volunteers

NCT06204419 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 86

Last updated 2024-01-12

No results posted yet for this study

Summary

The purpose of the study is to assess the safety, tolerability and pharmacokinetics of XH-S002 in healthy volunteers under SAD (Single ascending dose) and MAD (Multiple ascending dose) studies. In addition, this study evaluates the food effects of XH-S002.

Conditions

  • Healthy Adults

Interventions

DRUG

XH-S002 （A）

XH-S002 powder will be administered orally as per assigned treatment regimen.

OTHER

Placebo（B）

XH-S002 Placebo (matched) will be administered orally as per assigned treatment regimen.

Sponsors & Collaborators

  • S-INFINITY Pharmaceuticals Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-12-26
Primary Completion
2024-07-31
Completion
2024-10-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06204419 on ClinicalTrials.gov